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Introduction
Yearly sales of rituximab in the US already exceed 
$2  billion, attesting to its increasing US Food and Drug 
Administration (FDA)-approved and oﬀ -label use in 
multiple clinical settings such as B-cell lymphoma, 
lympho proliferative disorders, and refractory inﬂ amma-
tory conditions, including rheumatoid arthritis (RA) 
(Table 1) [1-5]. By mid-2011, 12,448 adverse events (AEs) 
asso ciated with rituximab use were publicly reported to 
the FDA; of these, febrile neutropenia, pyrexia, pneu-
monia, and anemia were the most common [6]. 
Rituximab had been implicated as the suspect drug 
leading to death in 476 cases [6].
Th e cost of hospitalization due to adverse events 
associated with rituximab can be substantial, especially 
when they require an intensive care unit (ICU) admission. 
In a prospective multicenter study of adverse events 
associated with rituximab, patients with infusion 
reactions required signiﬁ cantly more staﬀ  time per 
infusion compared with those in whom no reactions 
occurred (164 versus 123  minutes) [7]. Grade 3 and 4 
(severe, life-threatening) infusion reactions resulted in 
signiﬁ cantly higher infusion-associated human resource 
costs compared with when no infusion reactions 
occurred (median cost of $220 versus $120) [7]. In 
another study by the same authors, resuscitation carts 
needed to be used in 23% of patients (11 out of 47) with 
grade 3 or 4 infusion reactions. ICU admission occurred 
in two cases. Th e mean duration of hospitalization for a 
severe infusion reaction was 4  days [8]. Hence, the 
increasing frequency of use of rituximab in addition to its 
potentially serious adverse eﬀ ects – either alone or in 
combination with other agents – warrants that 
intensivists, along with hematologists and rheuma-
tologists, be familiar with the drug, especially when it is 
used in a critical care setting or when patients develop 
serious AEs (SAEs) requiring critical care management.
Mechanism of action
Rituximab is a chimeric monoclonal antibody directed 
against the CD20 B-cell antigen, a non-glycosylated 
phosphoprotein that is expressed on the surface of all 
mature B cells (Figure  1) [9]. It is not present on stem 
cells and is lost prior to B-cell diﬀ erentiation into plasma 
cells. Hence, rituximab causes a selective, transient 
depletion of both the normal and malignant CD20+ B-cell 
subpopulations and oﬀ ers a more speciﬁ c and targeted 
approach to B cell-driven disorders. In malignancies, 
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rituximab also synergistically acts to sensitize B cells to 
other chemotherapeutic regimens [3,9,10].
Figure 1 highlights the postulated mechanisms through 
which rituximab acts [9,11,12]: (1)  antibody-dependent 
cell-mediated cytotoxicity: presumed predominant mecha-
nism of action in vitro; (2) complement-dependent cyto-
toxicity; (3)  direct eﬀ ects of the drug: ligand binding 
leading to apoptosis or sensitization (or both) of the 
tumor to other chemotherapeutic agents; and (4) antibody-
dependent phagocytosis: through both Fc and comple-
ment receptors. Th ese eﬀ ects occur simultaneously and 
may complement one another, leading to a synergistic 
eﬀ ect. Th is has led to multiple randomized clinical trials 
showing the beneﬁ cial eﬀ ects of rituximab in many 
diseases, leading to its increasingly widespread use 
(Table 1) [13-15].
Dosing
Rituximab is administered as an intravenous infusion [9]. 
For treatment-naïve patients, it is started at a rate of 
50  mg/hour and is increased by 50  mg/hour every 
30 minutes to a maximum of 400 mg/hour. Patients are 
premedicated with an analgesic/antipyretic (for example, 
acetaminophen), antihistaminic (for example, diphen-
hydra mine), and a steroid (for example, methyl pred-
nisolone) 30  minutes prior to the infusion, mainly to 
minimize the severity of infusion reactions [8,9,16]. 
Often, a uricostatic agent (for example, allopurinol) and 
aggressive hydration are used prior to using rituximab for 
treating tumors with high cell burden, like lymphomas [9].
Uses within the critical care setting
Rituximab as part of chemotherapeutic regimens
Rituximab is often administered in the ICU in patients 
who have lymphoproliferative disorders and who need 
combination chemotherapy but who have tumor lysis 
syndrome or are at high risk for this syndrome [17,18] – 
for example, rituximab with cyclophosphamide, doxo-
rubicin, vincristine, and prednisone (R-CHOP), rituxi-
mab with cyclophos pha mide, doxorubicin, etopo side, and 
prednisolone (R-CHVP), rituximab with cyclophos pha-
mide, vincristine, and pred nisone (R-CVP), rituximab 
with ﬂ udarabine, cyclophos phamide, and mitoxantrone 
(R-FCM), and rituximab with mito xantrone, chloram-
bucil, and prednisolone (R-MCP). Rituximab is often 
administered to patients in an ICU when they have a 
newly diagnosed malignancy with an extensive disease 
burden, multi-organ involve ment, and/or disseminated 
intra vascular coagulation [19].
Refractory idiopathic thrombocytopenic purpura
Idiopathic thrombocytopenic purpura (ITP) refractory to 
steroids and splenectomy can be challenging to treat. 
Th ese patients may be transferred to an ICU for severe 
thrombocytopenia because of the risk of spontaneous 
intracranial bleeding. In patients with refractory ITP, 
response rates of up to 50% have been reported with 
rituximab [20].
Post-transplant lymphoproliferative disorder
Post-transplant lymphoproliferative disorder (PTLD) is 
being increasingly diagnosed (1% to 10% of transplant 
patients) in the setting of prolonged use of immuno-
suppressants. Rituximab in combination with other 
chemotherapeutic agents may be used in transplant 
ICUs, depending on disease severity. However, treatment-
associated mortality occurs in up to 11% of patients with 
PTLD [21,22].
Thrombotic thrombocytopenic purpura
Severe thrombotic thrombocytopenic purpura (TTP) is 
often diagnosed in the ICU or necessitates an ICU 
admission on presentation. In a phase  2 trial of 40 
patients with TTP, rituximab along with plasma exchange 
signiﬁ cantly decreased the duration of hospitalization 
and rate of relapse [23].
Severe interstitial lung disease associated with connective 
tissue disease
In a retrospective cohort study of patients with pro gres-
sive interstitial lung disease (ILD) associated with con-
nective tissue disease not responding to conventional 
immunosuppressive regimens, rituximab improved lung 
function in seven of eight patients [24]. Two of these 
patients were mechanically ventilated. Rituximab along 
Table 1. Common indications for rituximab therapy
Disease conditions
Chronic lymphocytic leukemia
CD20+ non-Hodgkin lymphoma (expressing the B-lymphocyte antigen CD20)
Rheumatoid arthritis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
 • Granulomatosis with polyangiitis (formerly Wegener’s 
  granulomatosis)
 • Microscopic polyangiitis
 • Eosinophilic granulomatosis associated with polyangiitis (formerly 
  Churg-Strauss syndrome) (unlabeled)
Chronic refractory graft-versus-host disease (unlabeled)
Refractory idiopathic thrombocytopenic purpura (unlabeled)
Hodgkin lymphoma (unlabeled)
Refractory pemphigus vulgaris (unlabeled)
Post-transplant lymphoproliferative disorder (unlabeled) 
Waldenström macroglobulinemia (unlabeled)
Type I diabetes mellitus (unlabeled)
Multiple sclerosis (unlabeled)
Renal transplant (unlabeled)
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with cyclophosphamide has also been anecdotally used in 
the ICU in the treatment of severe ILD associated with 
antisynthetase syndrome [25].
Pulmonary vasculitides
Rituximab has been successfully used in patients who 
have diﬀ use alveolar hemorrhage related to systemic 
lupus erythematosus and who were either intolerant to 
cyclophosphamide or refractory to conventional immuno-
suppressive regimens [26,27]. It is also the ﬁ rst proven 
safe and eﬀ ective alternative to cyclophosphamide to induce 
remission in patients with anti-neutrophil cyto plasmic 
antibody (ANCA)-associated vasculitis (Table 1) [28,29].
Special populations
Rituximab should be used with caution in older patients 
and in patients with cardiopulmonary disease [9]. Older 
patients (more than 55 years of age) have a higher rate 
of serious cardiopulmonary and infectious compli-
cations. Rituximab should also be avoided in any 
patient with severe infection [9]. It is a category C drug 
for pregnant women because animal studies have 
revealed deleterious effects on the fetus and controlled 
studies in women are lacking or unavailable [9]. 
Transient B-cell lymphocyte depletion has been 
reported in infants exposed to rituximab in utero [30]. 
Hence, it should be considered only if potential 
benefits outweigh risks to the fetus, such as in non-
Hodgkin lymphoma (NHL), refractory moderate-to-
severe RA, and granulomatosis with polyangiitis or 
microscopic polyangiitis [9]. Although rituximab is 
secreted into the breast milk of lactating monkeys, 
there are insufficient data for or against its use during 
breast feeding in humans [30].
Figure 1. The proposed mechanisms of action for rituximab, a chimeric monoclonal antibody, against the CD 20 receptor. (1) Antibody-
dependent cell-mediated cytotoxicity (ADCC). Eff ector cells include natural killer cells and phagocytic cells such as monocytes and macrophages 
that express Fc receptors. (2) Complement-dependent cytotoxicity (CDC). (3) Direct eff ects of binding (induction of apoptosis and sensitization to 
other chemotherapeutic agents). (4) Antibody-dependent phagocytosis (ADP).
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Methods
We searched PubMed using combinations of the follow-
ing keywords: rituximab, biologics, adverse eﬀ ects, side 
eﬀ ects, toxicity, fatal, death, ICU, shock, cardiotoxicity, 
hepatotoxicity, neurotoxicity, respiratory failure, and 
renal failure. Randomized controlled trials, original 
studies (prospective or retrospective), systematic 
reviews, review articles, and case reports of patients 
treated with rituximab as well as relevant references 
from these papers were scrutinized and included in our 
review.
A SAE was deﬁ ned as ‘any untoward medical occur-
rence that at any dose results in death, is life-threatening, 
requires inpatient hospitalization or prolongation of 
existing hospitalization, results in persistent or signiﬁ cant 
disability/incapacity, is a congenital anomaly/birth defect, 
or requires intervention to prevent permanent impair-
ment or damage’ [31]. We included the National Cancer 
Institute (NCI) Common Toxicity Criteria Grading 
System to describe the severity of AEs or toxicities 
whenever they were mentioned in the original articles; 
higher grades denoted greater severity of toxicity [31] 
(Table  2). If the severity was not graded, we gave a 
description of the SAE. We used the same criteria system 
as proposed by the NCI to group AEs into ‘system organ 
class’ (SOC), which is identiﬁ ed by anatomical or physio-
logical system, etiology, or purpose [32]. Th e adverse 
eﬀ ects that were likely to be seen during (or that would 
be associated with) an ICU admission were included in 
the review. We focused on grade 3, 4, and 5 adverse 
reactions (Table 2).
Results
Th irty randomized controlled trials and one open-label 
extension study were included in the review, along with 
data from post-marketing surveillance and other case 
reports (see Supplementary File  1). We excluded two 
articles that were not in English [33,34]. Th e most 
common reactions (incidence of at least 25%) in patients 
receiving rituximab monotherapy were infusion reactions 
and neutropenia [3,9]. Among these reactions, grade 3 
and 4 toxicities were found in 57% of patients (203 out of 
356) receiving rituximab [9]. Figure 2 outlines the major 
SAEs according to the SOCs of the NCI. Under each 
SOC, we ﬁ rst described reactions likely to occur soon 
after the adminis tration of rituximab. We then brieﬂ y 
enumerated complications that were associated with 
more extended administration and that may require 
intensive care.
Immunologic toxicity
Infusion reactions
Infusion reactions, ascribed to either anaphylaxis or 
allergic reactions, were the most common SAEs asso-
ciated with rituximab in 80% to 90% of randomized con-
trolled trials [4,35,36]. Many reactions developed within 
24 hours of the ﬁ rst infusion, were dose-dependent, and 
were often more common in those who received 
rituximab versus those receiving the conventional chemo-
therapy regimen [4,14,37-39]. Th e frequency of the 
reactions decreased with subsequent cycles, and life-
threatening anaphylaxis was rare [14,36,40]. Notably, 
approximately 80% of all fatal reactions occurred with the 
ﬁ rst infusion [9].
Th ere are also isolated case reports of severe or fatal 
SIRS (systemic inﬂ ammatory response syndrome)-like 
reactions (or both) developing within 24 hours of infusing 
rituximab [25,41]. Th ese are likely a part of the spectrum 
of the ‘cytokine release syndrome’ that has been 
described after rituximab infusions in patients with high 
tumor-cell burden [42]. Th e reported clinical features 
included fevers, chills, rigors, nausea, dizziness, pruritus, 
urticaria/rash, angioedema, laryngeal edema, sneezing, 
throat irritation/tightness, cough, hoarseness, broncho-
spasm, pulmonary inﬁ ltrates, hypoxia, and acute respira-
tory insuﬃ  ciency, with or without blood pressure changes 
or arrhythmias [4,9]. Th e severity of reactions was usually 
mild to moderate (grade 1 or 2); grade 3 to 4 reactions 
were rare and dose-dependent. For example, in a series of 
465 patients treated for RA, acute infusion reactions 
increased from 17% in placebo-treated patients to 23% 
and 32% in those receiving two 500-mg infusions and two 
Table 2. Common terminology Criteria for Adverse Events Version 4.0 (CTCAE) [31]
Grade of toxicity Brief description
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated 
Grade 2 Moderate; minimal, local, or non-invasive intervention indicated; limiting age-appropriate instrumental ADLa
Grade 3 Severe or medically signifi cant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; 
 disabling; limiting self-care ADLb 
Grade 4 Life-threatening consequences; urgent intervention indicated 
Grade 5 Death related to adverse event
a‘Instrumental ADL’ refers to activities of daily living such as preparing meals, shopping for groceries or clothes, using the telephone, and managing money. b‘Self-care 
ADL’ refers to bathing, dressing and undressing, feeding oneself, using the toilet, taking medications, and not being bedridden. From the National Cancer Institute 
Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009 NIH publication #- 09-7473.
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1,000-mg infusions of rituximab, respectively [36]. 
Interestingly, in studies of patients with AEs that are due 
to rituximab and that may lead to an ICU admission, 62% 
of patients (47 out of 76) receiving rituximab had a severe 
infusion reaction, but only two of these patients had a 
reaction that led to an ICU admission. Th is shows that 
many of these infusion reactions may potentially be 
manageable either under supervision in the outpatient 
setting or in monitored non-ICU hospital beds [43].
For mild infusion reactions, the rate of infusion was 
slowed or temporarily interrupted and was resumed at 
half the previous rate after symptoms abated. For 
moderate or severe infusion reactions, the infusion was 
held and subsequent infusions were not administered [9]. 
Patients were also given acetamino phen and intravenous 
antihistamine (for example, diphenhydramine) as well as 
epinephrine, broncho dilators, steroids, and oxygen if 
needed [8,9,16].
Th e frequency of infusion reactions, which form the 
bulk of major SAEs due to rituximab administration, 
decreased in patients who were premedicated with 
intravenous glucocorticoids [36]. For example, in the 
series of 465 patients treated for RA, serious infusion 
reactions decreased from 32% in the group receiving two 
500-mg infusions of rituximab and 37% in the group 
receiving two 1,000-mg infusions of rituximab to 19% 
and 29%, respectively, after premedication with intra-
venous glucocorticoids [36]. Th ese ﬁ ndings were corro-
bor ated by a series of renal transplant patients who 
received induction therapy with rituximab prior to 
transplantation and who experienced minimal or no side 
eﬀ ects and no signiﬁ cant infusion reactions [44]. Th ese 
patients received 100 mg of oral prednisolone as induction 
therapy for transplantation and this dose was reduced by 
10  mg per day to a daily dose of 20  mg, which was 
maintained for 1  month. Whether a similar protocol of 
pre medication with glucocorticoids minimizes SAEs in 
immunologically mediated diseases treated with rituxi mab 
remains to be seen, but has been recommended [9].
Blood and lymphatic system disorders
Grade 3 and 4 cytopenias lasting approximately 2 weeks 
have been seen in 48% of patients who had NHL and 
who received rituximab monotherapy, lymphopenia 
being the most common [9]. However, cytopenia was 
more common in chemotherapy trials of regimens in 
which rituximab was combined with agents more 
frequently associated with myelosuppression [39,45,46]. 
For example, granulocytopenia (grades 3 and 4) 
occurred in 72% of R-CHOP-treated patients compared 
with 57% of CHOP-treated patients in 64 patients with 
lymphoplasmacytic lymphoma/Waldenström macro-
globulinemia [45].
Whether these cytopenias have clinical implications is 
unproven [45,47,48]. In a study of 139 patients with 
mantle cell lymphoma, leukopenia (grades 3 and 4) 
occurred in 58% of patients receiving rituximab and a 
ﬂ udarabine-containing regimen (R-FCM) versus 41% in 
patients who received the ﬂ udarabine-containing regi-
men (FCM) (P  =  0.02) [47]. Th is was mainly due to 
lymphopenia rather than neutropenia; the frequency and 
severity of the latter were similar in the two groups. Th e 
rate of infections or febrile reactions was no greater in 
the group of patients receiving rituximab [47]. Th us, 
although rituximab-augmented chemo therapeutic regi-
mens may cause transient or sustained leukopenia or 
lymphopenia, the risk of develop ing serious infections or 
long-term outcomes is unclear. One reason for this 
discrepancy is that these studies are not powered to 
detect serious infections, as is evident by conﬂ icting 
results [38,47]. Another plausible reason is that, as seen 
with other drugs, the degree of immunosuppression 
induced by diﬀ erent doses of a drug may not necessarily 
correlate with the predisposition to develop a serious 
infection [49]. Also, the interaction between the under-
lying disease state and the pharmacotoxicity of an 
immunosuppressant – either as a single agent or in 
combination with another drug – may inﬂ uence this 
predisposition toward serious infections [38,50,51].
Figure 2. Major serious adverse events as categorized by the system organ class devised by the National Cancer Institute.
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Infections
Although studies have shown an increased frequency of 
infectious complications with rituximab within 1  year 
after completion of treatment, most infections either 
resolved or were treated without any major sequelae. 
Among 356 patients with lymphoid malignancies treated 
with rituximab, 31% developed bacterial infections, 10% 
developed viral infections, and 1% developed fungal 
infections; in 6%, the etiology was unknown [9]. In a trial 
of 620 patients with RA, the rate of serious infections was 
higher in the methotrexate (MTX)-rituximab group 
compared with the rate in the MTX-placebo group (5.2 
versus 3.7 per 100 patient-years) [14]. Six of the serious 
infections in the MTX-rituximab group – gastroenteritis, 
pyelonephritis, cat bite infection, inﬂ uenza, fever of 
unknown etiology, and de novo hepatitis B virus (HBV) – 
resolved without sequelae, and one (gangrenous cellulitis) 
resulted in a toe amputation [14].
Th ere is a dose-dependent increase in the frequency of 
infections in patients treated with rituximab for varying 
lengths of time [39]. Although older patients are at an 
increased risk of developing severe infectious compli ca-
tions, such infections are rarely fatal [4,15,46,52]. For 
example, in a study of 824 patients with diﬀ use large B-
cell lymphoma, three in the R-CHOP group died of sepsis 
[52]. Other fatal infections after rituximab administration 
include pneumonia and colitis [9].
In a review of serious viral infections associated with 
rituximab use, 64 cases were identiﬁ ed [53]. Th e median 
time from rituximab treatment to the diagnosis of the 
viral infection was approximately 5  months. Th e most 
frequently experienced viral infections were HBV infec-
tion (39.1%, n  =  25), cytomegalovirus infection (23.4%, 
n  =  15), varicella-zoster virus (9.4%, n  =  6), and others 
(28.1%, n = 18) [53]. Patients treated with rituximab carry 
a risk for HBV reactivation and hence should be screened 
for HBV prior to starting therapy [9]. Th is is based on a 
study from China in which, among 50 patients who had 
diﬀ use large B-cell lymphoma and who received 
rituximab, 60% had reactivation of the virus, 45% had 
severe hepatitis, and 25% died [54]. HBV reactivation is 
an indication for discontinuing therapy [9]. Patients with 
severe HBV have had up to 52% reported mortality 
compared with 33% in the other patients. Th ere is 
insuﬃ  cient evidence either for or against the use of 
rituximab in patients with latent hepatitis C virus 
infection [9].
Renal disorders
Urine output and trends in serum creatinine need to be 
closely monitored in patients receiving rituximab. Acute 
tumor lysis syndrome (ATLS) leading to acute kidney 
injury has been observed after rituximab monotherapy, 
especially in conditions with high tumor burden, like 
NHL [9]. ATLS results from ‘the rapid destruction of 
malignant cells, which abruptly release intracellular ions, 
proteins and metabolites into the extra-cellular space’ 
[55]. In high concentrations, acutely released uric acid 
can crystallize in renal tubules, leading to renal insuf-
ﬁ ciency. Early signs of ATLS include hyperkalemia, hypo-
calcemia, hyperphosphatemia, or hyperuricemia. Prophy-
lactic measures include intravenous hydration and anti-
hyperuricemic therapy (allopurinol) prior to the infusion 
[9]. Alkalization of the urine is controversial [55]. In 
high-risk cases (for example, acute leukemia with a white 
blood cell count of greater than 100,000/mm3, Burkitt 
lymphoma, or renal insuﬃ  ciency in the setting of inter-
mittent-risk disease), a single dose of 0.1- to 0.2-mg/kg 
recombinant urate oxidase (rasburicase), repeated if clini-
cally necessary, can be used to reduce uric acid burden in 
patients at high risk for ATLS [56]. Management of ATLS 
is mainly supportive and includes close monitoring of 
electrolyte abnormalities described above, volume status, 
and renal function as well as dialysis if necessary [55]. 
Providers should closely monitor for renal dysfunction 
when rituximab is com bined with cisplatin [9].
Cardiac disorders
Cardiac monitoring is necessary during and after 
rituximab infusions in all patients with a history of 
arrhythmias or angina [9]. In a study of 399 older patients 
with diﬀ use large B-cell lymphoma treated with either 
CHOP plus rituximab (R-CHOP) or CHOP alone, 
approxi mately 8% of patients in each group developed 
grade 3 or 4 cardiac AEs [57]. However, supraventricular 
arrhythmias and tachycardia were higher in the R-CHOP 
group versus CHOP alone. Similarly, a case of supra-
ventricular tachycardia was reported in a study of 
patients with RA [13].
Myocardial infarctions have also been reported but are 
rare [35-37], as were severe hypertension and cardiac 
tamponade [14]. Rare cases of fatal heart failure have 
been reported after using rituximab (either as mono-
therapy or combination chemotherapy), independent of 
pre-existing heart disease [58-60]. New-onset cardiogenic 
shock developed in a 20-year-old female treated with 
rituximab for TTP refractory to plasma exchange [61]. 
Both acute respiratory failure and biventricular cardio-
genic shock improved after rituximab was held and plasma 
exchange was continued. One case of fatal myo carditis was 
documented on autopsy in a study of 202 patients treated 
with rituximab for follicular lymphoma [60].
Respiratory, thoracic, and mediastinal disorders
In a 2011 review of 418 patients treated with rituximab 
mono therapy, 5.3% developed adverse pulmonary reac-
tions [23]. Approximately two thirds of the reactions 
were infectious, but nearly one quarter resulted in the 
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development of ILD. ILD subsequently improved although 
only half of those patients had received intra venous steroids 
[23]. Hypoalbuminemia was identiﬁ ed as an indepen dent 
risk factor for developing adverse pulmonary events.
Rare cases of status asthmaticus, bronchiolitis obliterans, 
hypersensitivity pneumonitis, and diﬀ use alveolar hemor-
rhage (fatal and non-fatal) have also been reported after 
using rituximab [9,36,62-64]. Bronchiolitis obliterans pre-
sent ing as cough, dyspnea, and pulmonary nodules has 
been described in patients receiving rituximab [62]. 
Hyper sensitivity pneumonitis presented as dyspnea, 
hypoxemia, eosinophilia, and pulmonary inﬁ ltrates [63]. 
Both bronchiolitis obliterans and hypersensitivity pneu-
mo nitis due to rituximab improved after stopping 
rituximab and administering steroids [62,63]. However, 
the response of diﬀ use alveolar hemorrhage to steroids 
was mixed [64].
Neoplastic disorders
In a 2012 review of trials of chemotherapeutic regimens 
containing rituximab, therapy-related neoplasms were 
identiﬁ ed in approximately 4.5% of patients (19 out of 
426) within a follow-up period of 44 months [65]. Most 
cases presented as either acute myeloid leukemia or 
myelodysplastic syndromes and had often previously 
achieved at least partial (if not complete) remission. Th e 
median survival time was approximately 7 months after 
diagnosis of the therapy-related neoplasms; however, this 
was not speciﬁ c to rituximab, since other agents were a 
part of the chemotherapeutic regimens. Th e presenting 
complaint and requirement for ICU admission in these 
cases are unknown; however, de novo acute myeloid 
leukemia may be diagnosed in the ICU when patients 
who have a history of cancer or who recently received 
chemotherapy present with acute respiratory failure, 
severe infection, bleeding, or renal dysfunction [66].
Gastrointestinal disorders
New-onset abdominal pain in patients receiving rituxi-
mab should prompt investigation for an acute abdomen. 
In post-marketing surveillance, 47 cases of bowel ob-
struc tion (nine deaths) and 37 cases of gastro intestinal 
perforation (four deaths) were reported by the end of 
2006 among patients treated with rituximab, mainly for 
NHL [67]. In another series of 98 patients treated with 
combination chemotherapy containing rituximab, there 
were ﬁ ve severe gastrointestinal compli cations, including 
one leading to a death [39]. Th e average onset of 
symptoms is approximately 6 days (range of 1 to 77 days) 
after the ﬁ rst dose [9].
Neurological disorders
Th e development of new neurological signs in patients 
receiving rituximab should be evaluated with 
neuro imaging and a lumbar puncture if there is no other 
obvious etiology. Among 465 patients treated with 
rituximab for active RA refractory to MTX, one case 
each of a cerebrovascular infarction, convulsion, epilepsy, 
and serotonin syndrome were reported [36]. Extremely 
rare cases of fatal ischemic and hemorrhagic strokes have 
been reported [9]. Patients have also presented with JC 
virus reactivation, leading to pro gressive multifocal 
leukoencephalopathy [68]. Th ese patients presented 
within 1 year of rituximab treatment for lymphoid 
malignancy or autoimmune disorders but had also 
received either immunosuppressive therapy or stem cell 
transplants. JC virus can be identiﬁ ed in the cerebrospinal 
ﬂ uid, and the diagnosis of progressive multifocal leuko-
encephalopathy is an indication to stop rituximab [9].
Dermatologic disorders
In a non-randomized, single-arm study of 356 patients 
treated for primary cutaneous B-cell lymphomas by using 
rituximab monotherapy, 37% developed itching, rash, or 
urticaria [69]. Serious cutaneous side eﬀ ects occurred in 
2% of the study population. Rituximab infusions have 
been associated with paraneoplastic pemphigus, lichenoid 
dermatitis, vesiculobullous dermatitis, Stevens-Johnson 
syndrome, and toxic epidermal necrolysis, from imme-
diately after the infusion until 3 months later [70]. 
Development of these severe reactions should prompt 
the discontinuation of rituximab [9].
Conclusions
Th e increasing use of biologics has allowed a more speciﬁ c 
and targeted approach to the treatment of various 
hematological malignancies and other auto immune 
disorders in which B-cell or humoral mecha nisms appear 
to play a role in disease pathogenesis. Overall, these 
biologics appear to be well tolerated and lead to fewer AEs 
compared with other, more conven tional therapies and 
chemotherapeutic regimens. However, their increasingly 
widespread and potentially prolonged use poses a new 
challenge and thus knowledge of SAEs related to rituximab 
is essential when dealing with patients suﬀ ering from such 
life-threatening complications.
At times, rituximab is administered in an ICU setting, 
and the intensivist may be the ﬁ rst to be alerted to the 
acute deterioration of a patient’s clinical status. Rarely, 
the intensivist may be the accepting physician of a 
potentially fatal complication in a patient who recently 
received rituximab. Th rough our review of the major 
studies of rituximab and its use in various settings (both 
as a single agent and in combination therapy), we hope to 
increase awareness among intensivists regarding the 
SAEs associated with its use. Early identiﬁ cation and 
management may help reduce morbidity and mortality 
associated with these events.
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